Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Shire PLC on In-Line Q4

Share:
Related
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
15 Stocks Moving In Friday's Pre-Market Session
Shire Plc (SHPG) Flemming Ornskov on Q1 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Deutsche Bank reiterated its Buy rating on Shire PLC (NASDAQ: SHPG), but lowered its price target from $110.00 to $108.00.

Deutsche Bank noted, “Shire reported largely in line Q4 non-GAAP EPS of $1.58. Total revs of $1.20B were also in-line. Vyvanse sales reached $257M (+18% Y/Y) but would have been $30M higher without a destock. As for other strong performers, Intuniv posted a 24% Y/Y increase to reach $81M (+$4M vs our est) and Elaprase sales reached $139M (+12% Y/Y), $7M better than our est. AXR revs of $82M came in $3M below consensus due to higher gross to net sales deductions. All other key product franchises were largely in-line. On the negative side, after 2 slow launch yrs in Europe, Resolor will no longer be promoted. Second, Dermagraft came in even weaker than expected, missing our $36M est by $17M.”

Shire PLC closed on Thursday at $93.68.

Latest Ratings for SHPG

DateFirmActionFromTo
Feb 2016Cantor FitzgeraldInitiates Coverage onBuy
Feb 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Feb 2016RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for SHPG
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (SHPG)

View Comments and Join the Discussion!